Inflammatory myopathies

Clinical features of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with macrophage activation syndrome

Clin Exp RheumatolPublished Retrospective case-control study

Authors' conclusion

Among anti-MDA5-positive DM, Infection, DM typical rashes, and higher serum levels of ferritin, AST, LDH, and CK were more common in patients complicated with MAS. The mortality of patients with MAS was high, particularly among patients who were older, given more combination therapy with TOF, and had RP-ILD, infection, heart failure and renal impairment.

Study context

Population
Patients with anti-MDA5 antibody-positive dermatomyositis (DM)
Participants
44 patients
Comparison
Anti-MDA5-positive DM with macrophage activation syndrome (MAS) vs without MAS
  • MASn = 11
  • Without MASn = 33reference
Outcome
Clinical features of anti-MDA5-positive DM with MAS
Methodological detailscontrols selected randomly in the same year at a ratio of 3:1
  • Controls selected randomly in the same year at a ratio of 3:1

Main finding

As reported in the abstract

Clinical features, MAS vs without MAS
MAS had significantly higher incidence of infection, heliotrope sign, Gottron's papule, V-neck sign, and higher serum ferritin, AST, lactic dehydrogenase (LDH) and creatine kinase (CK) than without MAS
p<0.05

Observational data: associations, not effects.

Further findings

Mortality among patients with MAS
36.4% · 4 of 11

Features of non-survivors vs survivors with MAS

Deceased patients were older, given more combination therapy with TOF and had higher incidence of RP-ILD, infection, HF and renal impairment than survivors
P < 0.05

Original publication

Clinical features of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with macrophage activation syndrome. Clin Exp Rheumatol. Published 24 August 2023. doi:10.55563/clinexprheumatol/2537nv

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.